Neuron
Volume 78, Issue 4, 22 May 2013, Pages 631-643
Journal home page for Neuron

Article
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta

https://doi.org/10.1016/j.neuron.2013.04.014Get rights and content
Under an Elsevier user license
open archive

Highlights

  • CD33 is expressed in microglia and exhibits increased expression in AD

  • Numbers of CD33-immunoreactive microglia positively correlate with Aβ plaque burden

  • CD33 inhibits microglial uptake of Aβ42

  • CD33 inactivation reduces insoluble Aβ42 levels in the APPSwe/PS1ΔE9 mouse brain

Summary

The transmembrane protein CD33 is a sialic acid-binding immunoglobulin-like lectin that regulates innate immunity but has no known functions in the brain. We have previously shown that the CD33 gene is a risk factor for Alzheimer’s disease (AD). Here, we observed increased expression of CD33 in microglial cells in AD brain. The minor allele of the CD33 SNP rs3865444, which confers protection against AD, was associated with reductions in both CD33 expression and insoluble amyloid beta 42 (Aβ42) levels in AD brain. Furthermore, the numbers of CD33-immunoreactive microglia were positively correlated with insoluble Aβ42 levels and plaque burden in AD brain. CD33 inhibited uptake and clearance of Aβ42 in microglial cell cultures. Finally, brain levels of insoluble Aβ42 as well as amyloid plaque burden were markedly reduced in APPSwe/PS1ΔE9/CD33−/− mice. Therefore, CD33 inactivation mitigates Aβ pathology and CD33 inhibition could represent a novel therapy for AD.

Cited by (0)